Establishment of a new quantitative detection approach to adefovir-resistant HBV and its clinical application

Figure 1 Targeted sequences of primers and probes designed for real-time polymerase chain reaction (PCR) to detect and quantify rtA181V/T and rtN236T adefovir (ADV)-resistance mutations.

Figure 2 Real-time fluorescent quantitative PCR amplification curves for the sensitivity of mixed variants (the upper part of each diagram) and patients (the lower part of each diagram) to the new method. A: Total HBV DNA; B: rtA181 mutation HBV DNA; C: rtN236T mutation HBV DNA.

Figure 3 Sequence analysis of ADV-resistant mutations. rtA181 wild strains (amino acid codon: GCT) with few rtA181T mutations (amino acid codon: ACT) in patient 1, rtA181V mutant (amino acid codon: GTT) in patient 2, rtA181T mutant (amino acid codon: ACT) in patients 3 and 4, rtA181 wild strains (amino acid codon: GCT) mixed with half of rtA181T mutant (amino acid codon: ACT) and rtN236 wild strains (amino acid codon: AAC) mixed with partial rtN236T mutants (amino acid codon: ACC) in patient 5, and rtA181 wild strains (amino acid codon: GCT) mixed with partial of rtA181T mutants (amino acid codon: ACT) in patient 6.